These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16942121)

  • 1. Using discrete choice experiments within a cost-benefit analysis framework: some considerations.
    McIntosh E
    Pharmacoeconomics; 2006; 24(9):855-68. PubMed ID: 16942121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science.
    McIntosh E; Donaldson C; Ryan M
    Pharmacoeconomics; 1999 Apr; 15(4):357-67. PubMed ID: 10537954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the societal and individual preferences for fertility treatment in Australia: study protocol for stated preference discrete choice experiments.
    Botha W; Donnolley N; Shanahan M; Chambers GM
    BMJ Open; 2018 Feb; 8(2):e020509. PubMed ID: 29444788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters.
    Hoch JS; Dewa CS
    Pharmacoeconomics; 2007; 25(10):807-16. PubMed ID: 17887803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].
    Willke RJ; Neumann PJ; Garrison LP; Ramsey SD
    Value Health; 2018 Feb; 21(2):155-160. PubMed ID: 29477393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Willingness to pay in the context of an economic evaluation of healthcare programs: theory and practice.
    Gafni A
    Am J Manag Care; 1997 May; 3 Suppl():S21-32. PubMed ID: 10180338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-benefit analysis.
    Robinson R
    BMJ; 1993 Oct; 307(6909):924-6. PubMed ID: 8241859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A stated preference binary choice experiment to explore NICE decision making.
    Tappenden P; Brazier J; Ratcliffe J; Chilcott J
    Pharmacoeconomics; 2007; 25(8):685-93. PubMed ID: 17640110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Willingness to pay as a measure of health benefits.
    Bala MV; Mauskopf JA; Wood LL
    Pharmacoeconomics; 1999 Jan; 15(1):9-18. PubMed ID: 10345161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options.
    Mühlbacher AC; Sadler A
    Value Health; 2017 Feb; 20(2):266-272. PubMed ID: 28237207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving Maternal Care through a State-Wide Health Insurance Program: A Cost and Cost-Effectiveness Study in Rural Nigeria.
    Gomez GB; Foster N; Brals D; Nelissen HE; Bolarinwa OA; Hendriks ME; Boers AC; van Eck D; Rosendaal N; Adenusi P; Agbede K; Akande TM; Boele van Hensbroek M; Wit FW; Hankins CA; Schultsz C
    PLoS One; 2015; 10(9):e0139048. PubMed ID: 26413788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of health services. Concepts and methodology applied to screening programmes.
    Griffiths DA
    Rev Epidemiol Sante Publique; 1981; 29(1):85-101. PubMed ID: 6789412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Principles of pharmacoeconomic analysis of drug therapy.
    Freund DA; Dittus RS
    Pharmacoeconomics; 1992 Jan; 1(1):20-31. PubMed ID: 10147037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone.
    Anton SF; Revicki DA
    Psychopharmacol Bull; 1995; 31(2):249-58. PubMed ID: 7491376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses.
    Bala MV; Zarkin GA; Mauskopf JA
    Value Health; 2002; 5(4):338-46. PubMed ID: 12102696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.
    Coyle D
    Pharmacoeconomics; 1996 Jun; 9(6):506-16. PubMed ID: 10160478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy?
    Donaldson C
    Pharmacoeconomics; 1998 Apr; 13(4):389-96. PubMed ID: 10178663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health economics--concepts and conceptual problems.
    Satpathy SK; Bansal RD
    Health Popul Perspect Issues; 1982; 5(1):23-33. PubMed ID: 10310083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.